The Cancer Genome Atlas (TCGA) project has revealed the mRNA and miRNA expression, promoter methylation, and DNA copy number in 489 patients with high-grade serous ovarian adenocarcinomas [237] and it has been stated that TP53 mutation has been detected in nearly 96% of tumors plus recurring somatic mutations of NF1, RB1, CDK12, BRCA1, and BRCA2 [124]. Here, CDK12 is linked to ovarian serous adenocarcinoma.